{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:42:06Z","timestamp":1777527726576,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ijtb.2023.03.002","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T13:14:42Z","timestamp":1679404482000},"page":"409-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacovigilance monitoring and treatment adherence in patients on anti-tubercular drugs"],"prefix":"10.1016","volume":"70","author":[{"given":"Pritpal Singh","family":"Matreja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohin","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazher","family":"Maqusood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijtb.2023.03.002_bib1","doi-asserted-by":"crossref","DOI":"10.2471\/BLT.07.043802","article-title":"Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment","volume":"86","author":"Awofeso","year":"2008","journal-title":"Bull World Health Organ"},{"issue":"3","key":"10.1016\/j.ijtb.2023.03.002_bib2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/ijerph14030248","article-title":"Detection of low adherence in rural tuberculosis patients in China: application of Morisky medical adherence scale","volume":"14","author":"Xu","year":"2017","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.ijtb.2023.03.002_bib3","unstructured":"Sachdev C. Why does India lead the World in death from TB? Available at: https:\/\/www.npr.org\/sections\/goatsandsoda\/2017\/11\/09\/561834263\/why-does-india-lead-the-world-in-deaths-from-tb. (Last Accessed on 24th January, 2021)."},{"key":"10.1016\/j.ijtb.2023.03.002_bib4","unstructured":"Available at: https:\/\/www.tbfacts.org\/about-us\/. (Last Accessed on 24th January, 2021)."},{"key":"10.1016\/j.ijtb.2023.03.002_bib5","unstructured":"Mahmood D. 40% of India's population play host ot the TB bacillus as a latent TB. Available at: https:\/\/www.oneindia.com\/feature\/40-percent-of-india-s-population-play-host-the-tb-bacillus-as-latent-tuberculosis-2049544.html. (Last Accessed on 24th January, 2021)."},{"key":"10.1016\/j.ijtb.2023.03.002_bib6","unstructured":"Tuberculosis in India. Available at: https:\/\/en.wikipedia.org\/wiki\/Tuberculosis_in_India. (Last Accessed on 24th January, 2021)."},{"issue":"2","key":"10.1016\/j.ijtb.2023.03.002_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/1947-2714.93376","article-title":"Medication adherence and its determinants among patients on concomitant tuberculosis and antiretroviral therapy in South West Ethiopia","volume":"4","author":"Kebede","year":"2012","journal-title":"N Am J Med Sci"},{"issue":"5","key":"10.1016\/j.ijtb.2023.03.002_bib8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive value of a medication adherence measure in an outpatient setting","volume":"10","author":"Morisky","year":"2008","journal-title":"J Clin Hypertens"},{"issue":"11","key":"10.1016\/j.ijtb.2023.03.002_bib9","first-page":"976","article-title":"Adverse drug reaction monitoring of antitubercular drugs during intensive phase at tertiary care medical college hospital: a prospective study","volume":"10","author":"Manju","year":"2020","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"10.1016\/j.ijtb.2023.03.002_bib10","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.18203\/2320-6012.ijrms20163312","article-title":"Profile of adverse drug reactions in patients on anti-tubercular drugs in a sub Himalayan rural tertiary care teaching hospital","volume":"4","author":"Sood","year":"2016","journal-title":"Int J Res Med Sci"},{"key":"10.1016\/j.ijtb.2023.03.002_bib11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.18203\/2319-2003.ijbcp20170829","article-title":"Pharmacovigilance of first line anti-tubercular therapy in category I patients of pulmonary tuberculosis","volume":"6","author":"Agarwal","year":"2017","journal-title":"Int J Basic Clin Pharmacol"},{"key":"10.1016\/j.ijtb.2023.03.002_bib12","article-title":"Pharmacovigilance and morroccan tuberculosis public program: current situation","author":"Tanani","year":"2014","journal-title":"Tuberc Res Treat"},{"key":"10.1016\/j.ijtb.2023.03.002_bib13","first-page":"8","article-title":"Tuberculosis treatment adherence of patients in kosovo. tuberculosis research and treatment","volume":"2017","author":"Krasniqi","year":"2017","journal-title":"Tuberc Res Treat"},{"issue":"2","key":"10.1016\/j.ijtb.2023.03.002_bib14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.13005\/bpj\/2173","article-title":"Adverse drug reaction monitoring in patients on antitubercular treatment in tertiary care hospital, Mandya","volume":"14","author":"Kiran","year":"2021","journal-title":"Biomed Pharmacol J"},{"key":"10.1016\/j.ijtb.2023.03.002_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41533-020-0179-x","article-title":"Interventions to improve medication adherence in tuberculosis patients: a systematic review of randomized controlled studies","volume":"30","author":"Pradipta","year":"2020","journal-title":"NPJ Prim Care Respir Med"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570723000239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570723000239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:34:03Z","timestamp":1777394043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570723000239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0019570723000239"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2023.03.002","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacovigilance monitoring and treatment adherence in patients on anti-tubercular drugs","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2023.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}